GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

SAN FRAN­CIS­CO – GSK will pay $1 bil­lion up­front to buy clin­i­cal-stage asth­ma drug­mak­er Aio­los Bio, the British drug­mak­er said ear­ly Tues­day morn­ing. It could pay up to $400 mil­lion more if mile­stones are met.

The deal marks one of the quick­est start­up un­veil­ing-to-buy­out jour­neys in re­cent biotech mem­o­ry. The San Fran­cis­co and Lon­don biotech emerged just three months ago with one of 2023’s largest pri­vate fi­nanc­ing rounds at $245 mil­lion. At­las Ven­ture, Bain Cap­i­tal Life Sci­ences, For­bion, Sofinno­va In­vest­ments and RA Cap­i­tal Man­age­ment backed the Se­ries A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.